<i><scp>HCV E1E</scp>2‐<scp>MF</scp>59</i> vaccine in chronic hepatitis <scp>C</scp> patients treated with <scp>PEG</scp>‐<scp>IFN</scp>α2a and <scp>R</scp>ibavirin: a randomized controlled trialP. Colombatto, Ferruccio Bonino, Rino Rappuoli et al.|Journal of Viral Hepatitis|2013Cited by 22
Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to α‐interferon treatment in patients with chronic hepatitis CA. Airoldi, Giovambattista Pinzello, Claudio Zavaglia et al.|European Journal of Immunogenetics|2004Cited by 15
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter studyPietro Lampertico, Massimo Colombo, Mauro Viganò et al.|F1000Research|2012Cited by 3
Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 monthsPietro Lampertico, Massimo Colombo, R. Soffredini et al.|F1000Research|2012Cited by 2
602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPYP. Colombatto, Ferruccio Bonino, Maurizia Rossana Brunetto et al.|Journal of Hepatology|2009Cited by 1